Butamben/Ketamine

氨基苯甲酸丁酯/氯胺酮

Report date: 2022/03/01 16:08:46

Base Information

Drug NameButamben/Ketamine
Drug Alias NameKetamine/Butamben氨基苯甲酸丁酯氯胺酮氯胺酮氨基苯甲酸丁酯Ketamine and Butamben氯胺酮/氨基苯甲酸丁酯 +[7] 
ClassificationSmall molecules
Mechanisms of ActionGlutamate [NMDA] receptor antagonistsSodium channel alpha subunit blockers
TargetsSodium channel alpha subunitGlutamate [NMDA] receptor
Therapy Area/IndicationsNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes ButambenKetamine Hydrochloride
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEpicept
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEpicept
Active IndicationsN/A
Inactive IndicationsNeuralgia

Other Information

ATC CodeN/A
Related LinksN/A